Track topics on Twitter Track topics that are important to you
Regeneron Pharmaceuticals's third quarter earnings report is a bright spot in what has been a dim month for the iShares Nasdaq Biotechnology ETF . The stock popped in morning market action, lifted 2.7% to $415.42 a share by estimate-beating results.
Original Article: Biotech: A Bright Spot...From Regeneron?NEXT ARTICLE
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...